B6.Cg-Tg(B2M,HLA-B*27:05)56-3Trg/DcrJ

Stock number: 003428
Product name: line 56-3
Research areas: Immunology, Inflammation and Autoimmunity Research

Description

These line 56-3 mice express a transgene containing the human B2M and HLA-B2705 sequences with high expression of HLA-B27.

Detailed description

This transgenic strain carries the human B2M and HLA-B27:05 sequences. Transgenic constructs were co-injected and co-integrated; and founder line designated 56-3. Cell surface expression of B27 is several fold higher than mice expressing B27 alone. This transgenic insertion event is homozygous lethal.

Development

The HLA-B2705 and human B2M constructs were co-injected into fertilized (C57BL/6 x SJL/J)F2 eggs by Dr. Joel Taurog (University of Texas, Southwestern) and co-integrated onto the same chromosome. The founder line was designated 56-3. Mice were backcrossed to C57BL/6 mice for at least 5 generations.

Allele

Symbol: Tg(B2M,HLA-B*27:05)56-3Trg
Name: transgene insertion 56-3, Joel D Taurog
MGI accession ID: MGI:5770329
Generation method: Transgenic
Attributes: Inserted expressed sequence; Humanized sequence
Marker symbol: Tg(B2M,HLA-B*27:05)56-3Trg
Marker name: transgene insertion 56-3, Joel D Taurog
Chromosome: UN
Strain of origin: (C57BL/6 x SJL/J)F2
Expressed genes: B2M,beta-2-microglobulin,human; HLA-B,major histocompatibility complex, class I, B,human
Molecular note: The HLA-B*27:05 and human B2M constructs were co-injected and are believed to have co-integrated because they have co-segregated through extensive breeding. Splenic expression of both was confirmed. This insertion is believed to be homozygous lethal.
General note: Because separate constructs were injected this transgenic insertion was called by two separate marker sybmols for many years, Tg(B2M)1Trg and Tg(HLA-B27)1Trg, but this was corrected in 2016 to a single marker indicative of probable co-integration.